European Archives - Page 1111 of 1194 - European Medical Journal

EMJ

ECC 2015: News briefing chaired by Prof Martine Piccart

At the European Cancer Congress (ECC) 2015, Martine Piccart, MD, PhD, of Université Libre de Bruxelles and Institut Jules Bordet, Brussels, Belgium…

EMJ

ECC 2015: CheckMate 025 trial showed nivolumab improved overall survival in advanced kidney cancer

CheckMate 025, a phase 3 clinical trial, compared the anti-programmed cell death protein-1 (PD-1) antibody, nivolumab, with the standard treatment…

EMJ

ECC 2015: EUROCARE-5 trial showed large variations in blood cancer survival in Europe

Comparisons of cancer patients’ survival and care in Europe up to 2007 showed that although more patients are surviving for at least five years after…

EMJ

ECC 2015: METEOR trial showed cabozantinib improved survival in advanced kidney cancer

METEOR, a phase 3 clinical trial, compared cabozantinib with everolimus for the treatment of patients with advanced clear cell renal cell carcinoma.

EMJ

The value of an intermediate Recurrence Score® result in the Oncotype DX® Breast Cancer Assay

The Oncotype DX® Breast Cancer Assay is a 21-gene assay that provides a Recurrence Score® (RS), which is divided into low-, intermediate- and high-risk…

EMJ

TERRAIN trial of enzalutamide versus bicalutamide for advanced prostate cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Neal Shore, MD, FACS, of Atlantic Urology Clinics, Myrtle Beach, SC…

EMJ

Assessing the eligibility of a breast cancer patient for genomic testing

Genomic tests, such as the Oncotype DX® Breast Cancer Assay, provide results that quantify recurrence risk and identify patients who are likely or…

EMJ

Updated results of a phase 1a study of anti-PDL1, MPDL3280A, in urothelial bladder cancer

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, Queen Mary University…

EMJ

Experience of the Oncotype DX® Breast Cancer Assay in the clinic

At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA…

EMJ

European Liver Patients’ Association (ELPA) Launches Call to Action Report for the Treatment of Hepatic Encephalopathy

BRUSSELS, BELGIUM, 12 October 2015, 18:30 CET – ELPA today launched a new call to action report ‘Time to DeLiver: Getting a Grip on HE’ at the…